Xcelerate

What Xcelerate does

Xcelerate (OTCMKTS: XCRT) is a publicly traded company founded in 1996 and headquartered in Coral Springs, Florida. It holds a 51% controlling interest in AfiyaSasa Africa LLC, an AI- and AR-supported healthcare platform designed to connect patients and physicians via mobile devices in underserved markets, with its first pilot program in Tanzania.

The platform's core technology is delivered through a partnership with AdviNOW Medical and combines artificial intelligence with augmented reality to enable remote patient–physician interaction on mobile endpoints. Xcelerate has begun assembling supporting capabilities around this core, including a Chief Science Officer (Dr. Anja Glisovic), a consulting agreement with a Tanzanian physician (Dr. Desire Ruhinda) for clinical onboarding, and a small IP portfolio of 2 granted patents and 2 pending applications.

The business model is pre-commercial: Xcelerate has no publicly disclosed revenue, has just entered clinical validation (with first clinical patient onboarding targeted for Q3 2026), and is refocusing its capital base after divesting its interest in ESN Group in December 2025. The company employs between 11 and 50 people and serves healthcare providers and patients in emerging markets, principally Sub-Saharan Africa, via its consolidated subsidiary.

Name

Xcelerate

Legal name

Xcelerate, Inc.

Website

https://xcelerate.global

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

1–10 employees

Short description

Xcelerate (OTCMKTS: XCRT) is a publicly traded company that controls AfiyaSasa Africa LLC, an AI/AR-enabled mobile healthcare platform targeting underserved African markets, currently in clinical validation with a Tanzania pilot and first patient onboarding targeted for Q3 2026.

Ownership category

akta.pro rank

Product category

Digital Health Platform

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Software Publishers (5132), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Services-Prepackaged Software (7372)

akta.pro primary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

akta.pro secondary industries

Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways) (HLACAFAO), Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps) (HLAHAIAM)

Keywords

• Ai healthcare platform
• Virtual health consultations
• Mobile clinical platform
• Telemedicine solutions
• Digital health platform

Headquarters

HQ city

Coral Springs

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Healthcare Technology Solutions: Revenue generated through development and deployment of AI-assisted healthcare projects, including potential licensing of medical technology platforms and associated services in underserved healthcare markets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Xcelerate develops and deploys an AI and AR-enabled clinical platform that connects patients and physicians via mobile devices to extend healthcare access in underserved African markets. The platform, originally developed by AdviNOW Medical, is operated through its majority-owned subsidiary AfiyaSasa Africa LLC (51% interest) and is currently being clinically validated in Tanzania, with first patient onboarding anticipated in Q3 2026. The company also holds an IP portfolio covering wound treatment methods, viral infection methods, and pending surgical tools with targeting guidance.

Product overview

Xcelerate operates as a healthcare technology company with a portfolio focused on AI-assisted medical solutions. The primary offering is the AfiyaSasa Africa Platform, a medical technology and virtual health system that uses AI and AR to connect patients and physicians via mobile devices. This platform was developed by AdviNOW and is being deployed through an AI-supported clinical platform in Tanzania. The company also maintains intellectual property related to wound treatment, viral infection methods, and surgical tools with targeting guidance. Xcelerate sold its interest in ESN Group to strengthen its financial position and is pursuing digital engagement initiatives alongside its core healthcare AI projects.

Differentiator

Problem solved

Functional benefit

Products and services

• AfiyaSasa Africa Platform An AI and AR-enabled medical technology and virtual health platform that connects patients and physicians via mobile devices for clinical consultations. Developed by AdviNOW Medical and majority-owned (51%) by Xcelerate through subsidiary AfiyaSasa Africa LLC, it is targeted at extending healthcare access in underserved African markets. It is currently being clinically validated in Tanzania with first patient onboarding anticipated in Q3 2026.

Quantifiable outcome

• First clinical patient onboarding anticipated Q3 2026

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature2 records

Partnerships

Four partnerships are on record, tiered core.

• Local Technical Partners (Tanzania)coreStrategic or Co-development Partner · 24 June 2026Local technical partners in Tanzania supporting the AfiyaSasa Africa healthcare program deployment, working with Xcelerate and AdviNOW Medical on system integration and clinical validation.
• Local Clinical Partners (Tanzania)coreStrategic or Co-development Partner · 24 June 2026Local clinical partners in Tanzania coordinating with Xcelerate for the AfiyaSasa Africa healthcare program, transitioning from system integration to initial clinical validation.
• Dr. Desire RuhindacoreImplementation/ SI/ Consulting Partner · 4 May 2026Tanzanian medical doctor engaged under consulting agreement to support AfiyaSasa Africa initiative by reviewing AdviNOW Medical system capabilities, identifying localization requirements aligned with Tanzanian treatment guidelines, and identifying clinical sites for potential pilot program.
• AdviNOW MedicalcoreTechnology or Integration · 3 January 2022AdviNOW developed the AI and AR platform for AfiyaSasa Africa, a start-up specializing in medical technology and virtual health. Xcelerate acquired 51% interest in AfiyaSasa Africa, which uses this platform to extend healthcare access in Africa.

Scale indicators4 records

Recent moves7 records

Expansion highlights3 records

Direct peers

• K Health: K Health delivers AI-first virtual primary care via a mobile platform that connects patients with physicians using AI-supported triage and clinical decisioning — directly analogous to Xcelerate's AI/AR physician-connection model, though focused on US payors.
• 98point6: 98point6 is a text-based, AI-augmented virtual care platform connecting patients with physicians via mobile devices. Mirrors Xcelerate's mobile, AI-supported clinical workflow architecture in a more mature US commercial setting.
• Forward (Forward Health): Forward is a tech-enabled primary care company combining AI-driven clinical workflows with physician consultations delivered through connected hardware and mobile apps — comparable technology stack and care-delivery thesis to Xcelerate's AI/AR clinical platform.
• AdviNOW Medical: AdviNOW is Xcelerate's core technology partner and developed the AI/AR platform deployed through AfiyaSasa Africa. Operates in the same AI-enabled clinical workflow and virtual care space, serving as both collaborator and adjacent competitor for physician-shortage markets.

Emerging players

• Helium Health: Helium Health provides electronic medical records and telehealth solutions to hospitals and clinics across West Africa. Targets the same underserved African healthcare delivery market where Xcelerate is deploying its platform.
• Zipline: Zipline operates autonomous drone-based medical delivery in several African countries, addressing healthcare access gaps in underserved markets. While the modality differs, the focus on extending healthcare into infrastructure-constrained African geographies is highly comparable to Xcelerate's Tanzania focus.

Broad incumbents

• Doctor On Demand (Included Health): Doctor On Demand, now part of Included Health, delivers virtual physician visits via mobile. While broader in scope, its direct-to-patient virtual care model overlaps with Xcelerate's mobile-first patient-to-physician connection thesis.
• Amwell (American Well): Amwell is a leading enterprise telehealth platform connecting patients and clinicians across health systems and payers. Its broader portfolio of virtual care offerings provides a scaled incumbent benchmark for Xcelerate's mobile telehealth play.
• Teladoc Health: Teladoc is the largest publicly-listed telehealth incumbent, offering virtual physician consultations across multiple specialties and geographies. Serves as the established scaled comparable for the virtual-care category Xcelerate is entering.

Regional players

• mPharma: mPharma operates a healthcare supply-chain and pharmacy-tech platform across multiple African markets. While focused on pharmaceutical distribution rather than virtual care, its pan-African healthcare footprint provides a regional comparison for market entry and scaling across underserved geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key highlights6 records

Customer concentration

• Xx.com/xcelerateus
• LinkedInlinkedin.com/company/xcelerateinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xcelerate